KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Current Liabilities (2018 - 2025)

Castle Biosciences' Total Current Liabilities history spans 7 years, with the latest figure at $68.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 39.04% year-over-year to $68.7 million; the TTM value through Dec 2025 reached $68.7 million, up 39.04%, while the annual FY2025 figure was $68.7 million, 39.04% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $68.7 million at Castle Biosciences, up from $55.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $68.7 million in Q4 2025 and bottomed at $17.6 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $36.2 million (2022), against an average of $37.1 million.
  • The largest annual shift saw Total Current Liabilities tumbled 33.95% in 2021 before it skyrocketed 124.83% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $24.9 million in 2021, then skyrocketed by 45.17% to $36.1 million in 2022, then soared by 31.94% to $47.7 million in 2023, then grew by 3.62% to $49.4 million in 2024, then soared by 39.04% to $68.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Total Current Liabilities are $68.7 million (Q4 2025), $55.3 million (Q3 2025), and $50.9 million (Q2 2025).